On May 4, 2021 Obsidian Therapeutics, a biotechnology company pioneering engineered cell and gene therapies, reported that the Company will present at the upcoming 24th American Society of Gene and Cell Therapy (ASGCT) (Free ASGCT Whitepaper) Annual Meeting, which will be hosted virtually May 11-14, 2021 (Press release, Obsidian Therapeutics, MAY 4, 2021, View Source [SID1234579108]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The abstract for the poster describes how Obsidian’s cytoTIL15 product (cytoTIL therapy engineered with mbIL15) demonstrates enhanced in vivo performance in the absence of IL-2, paving the way for more durable efficacy and improved safety in patients with solid tumor malignancies, and has been published in Molecular Therapy.
Details of the poster:
Title: cytoTIL therapy engineered with mbIL15 demonstrates enhanced in vivo persistence in the absence of IL-2, paving the way for durable efficacy and improved safety in patients with solid tumor malignancies
Abstract Number: 617
Session: Cancer – Immunotherapy, Cancer Vaccines
Session Date and Time: Tuesday May 11, 2021 8:00 AM – 10:00 AM
Abstract Summary: Tumor-infiltrating lymphocytes (TILs) have generated promising data in clinical trials as therapy for heavily pretreated patients with solid tumor malignancies, such as metastatic melanoma. The IL-2 regimen required for in vivo maintenance of TILs poses significant limitations on application of the therapy. Obsidian’s cytoTIL product is comprised of TILs engineered with membrane bound IL-15 (mbIL15) that is regulatable using a drug responsive domain (DRD) designed via our cytoDRiVE platform. cytoTILs demonstrate enhanced persistence in mice without IL2 compared to conventional TILs with IL2.
Paul Wotton, Chief Executive Officer of Obsidian, commented, "We expect that cytoTIL15 will pave the way for a more potent and persistent TIL product that will not require infusion of IL-2, thereby improving durable efficacy and expanding the pool of eligible patients with metastatic melanoma and other solid tumor malignancies that can be treated with this groundbreaking therapy."